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Amended proposal for a 
EUROPEAN PARLIAMENT AND COUNCIL DIRECTIVE 
amending DIRECTIVE 90/220/EEC 
on the deliberate release into the environment of  genetically modified organisms 
(presented by the Commission pursuant to Article 189 a (2) 
ofthe EC-Treaty) EXPLANATORY MEMORANDUM 
Pursuant to  Article  189a paragraph 2 of the  Treaty, the  Commission submits an  amended 
Proposal for a European Parliament and Council Directive amending Directive 90/220/EEC on 
the deliberate release into the environment of genetically modified organisms (GMOs). The 
amended Proposal takes account of a number of amendments from  the European Parliament 
, adopted at its Plenary Session on 11  February 1999. 
In general the Commission cannot accept amendments that seek to change the balance of the 
safety net built into the Commission Proposal or which are not in line with the basic principles 
of the  Directive  such  as  the  case  by  case  analysis.  However,  the  Commission can accept 
Amendments 1, 3 to 6, 11, 12, 14 to  17, 20, 25 to 27, 29, 31, 32, 35, 38, 39, 42 to 44, 53, 54, 57, 
58, 60, 62, 64 to 66, 89, 92 and 94 either fully or in principle. In addition the Commission can 
partially accept Amendments 9, 33 and 34. Comments on these amendments are (,!S follows. 
Amendment~ 1,  14, 38, 64, 66 and 92 seek to establish means to facilitate the identification, 
control  and  retrieval  of GMOs.  The  Commission  agrees  to  the  principle  to  strengthen 
administrative control within the Directive. It has accepted these amendments in so far as they 
do not complicate the operation of the Directive or duplicate provisions already present in the 
Commission Proposal and has amended Article 2 (5) and Annex IV accordittgly and introduced 
the new recitai 4a. 
Amendments 3 and 94 strengthen the link of  this Directive to product legislation and thus ensure 
a comprehensive environmental risk assessment throughout the legislative framework concerning 
biotechnology. Therefore, the Commission has accepted these amendments in principle and 
reworded Articles 5, 10 and the corresponding recital 5, and introduced the new recital Sa. 
Amendment 4, which is fully acceptable to the Commission, confirms in the new recital 5b that 
all conditions, including monitoring and time limitation may be revised prior to the renewal of 
consent. 
Amendments 5 and 42 delete the reference to the fixed 7 year time limitation of  consent in recital 
7 and Article 13c, both of  which concern the renewal of  consent. The Commission can accept an 
optional time limitation for the renewal of  consent and has reworded recital 7 and Articles 13c 
and 13e accordingly. 
Amendments 6 and 54 are acceptable in so  t~1r as they confirm that the Council and the European 
Parliament may request the Commission to  consult the  Ethic~.! Committee in order to obtain 
advice on general ethical concerns related to the release of GMOs (recital 12 and Article 20a). 
The Commission, however, cannot agree to link this consultation to the decision-making on the 
placing on the market of individual GMOs or to a time limit for delivering an Opinion by the 
Ethical Committee. 
2 Amendment 9 clarifies the definition of"organism" in Article 2 (1), which does not cover human 
beings. The second part of  this amendment substantially duplicates the first part and is, therefore, 
not acceptable. 
Amendments 11, 12,  15 and  16 change the definition of  "environmental risk assessment" and 
/(¥" 
introduce new definitions into Article 2 with a view to clarifying the objective and the text of  the 
Directive. Tl)e Commission supports these clarifications. However, Amendments 11  and 15 have 
been reworded to make them consistent with the text of  the Commission Proposal. 
Amendments 17, 57 and 62 highlight the precautionary approach as a basis for the approval 
process. The Commission strongly supports the principle behind these amendments, but is of  the 
opinion that the Directive as  a  whole reflects the precautionary principle.  Accordingly the 
Commission has addressed this issue in recital I which encompasses the framework within which 
the Directive operates. 
Amendment 20 introduces an obligation for Member States and requires that necessary measures 
are taken in the event of an unauthorised release of GMOs. The amendment also .requires that 
other Member States, the Commission and the public be informed. The Commission accepts the 
principle ofthis amendment and has reworded Article 4 (3) accordingly.  ' 
Amendments 25  and  26  require  that  information  on  remediation  plans  and  details  of the 
monitoring plans are included in the notification dossier for Part B releases (Article 6b (2)). The 
Commission  accepts  these  amendments  in  principle,  since  they  clarity  the  information 
requirements concerning part B releases. 
Amendments 27, 29 and 32 concerning the public consultation for experimental releases is 
acceptable in principle. The Commission has reworded Article 7 in order to align it with the 
provisions of the Aarhus Convention relating to  public participation in decision-making in 
environmental matters. 
Amendment 31  clarifies that the competent authorities of Member States have to evaluate all 
additional information which becomes available after consent has been granted. The Commission 
strongly supports this amendment, which provides a useful clarification in Article 6d (2). 
Amendment 33  is partially acceptable insofar as  it specifies that reports on releases and the 
intervals that should be applied to such reports are set out in the authorisation. The Commission 
has also included in  Article 8 that the summaries of the  results should be circulated  to  the 
Member States (Amendment 35). The Commission strongly supports the principle behind this 
amendment, since it will promote the link between Part B and  Part C of the Directive and 
contribute towards harmonisation. The reference to long term consequences in Amendment 33 
is covered in Articles 6b and 6d of  the amended CoiTimission Proposal. 
Amendment 34, part 1 amends Article 9 (2) providing an opportunity for Member States to 
request full dossiers on experimental releases. The Commission accepts this amendment, since 
it will assist harmonisation of  the regulatory assessment and control but clarifies that the dossier 
should be provided by the competent authorities of  the relevant Member State. The second part 
of  Amendment 34 would enable Member States to stop the clock for comments on experimental 
3 releases in other Member States. This, however, would not be practical within the procedures of 
the Directive and is therefore not acceptable. 
Amendment 39 (Article 12 (3)) specifies further the content of the risk assessment report by 
introducing the requirement to indicate that the GMO in question is not to be placed on the 
market. The Commission accepts this change and additionally has introduced a new paragraph 
3a in Article 12 and reworded Annex VI, paragraph 5 in order to make the text consistent with 
this amendment. 
Amendment 43 addresses the need for termination of  the release of  a GMO and, in the event of 
an acute risk, the recovering of  GMOs released as far as possible. A requirement to inform the 
public is also included in this amendment. Amendment 53 replaces the word "new" in Article 16 
with the word "additional", which seeks to ensure that Member States take decisions regarding 
provisional restrictions of use of a certain GMO in  line with best available knowledge. The 
Commission accepts  the  principle  behind  these  amendments  and  has  reworded  Article  I 6 
accordingly. 
Amendment 44 clarifies the circumstances when the Scientific Committees may be consulted by 
the Commission and sets a time limit for such consultations. The Commission agrees in principle 
that the procedure for the consultation of the relevant Scientific Committees can be clarified 
further  and  that in certain  cases  a  specific  time  limit for  delivering  an Opinion could be 
appropriate. Articles 13d and 20a were, therefore, amended accordingly. 
Amendment 58 introduces the element "pathogenicity to micro-organisms" in the chapter of 
potentially harmful effects in Annex II on the principles of  the environmental risk assessment. 
.This is a useful clarification and the Commission, therefore, supports this amendment. 
Amendment 60' introduces a requirement in Annex II that the release of  a GMO should be halted 
and as far as possible reversed if  the estimated risk is not acceptable. It  may only be carried out 
after the conditions have been modified in such a way as to reduce the risks significantly. This 
amendment mainly duplicates provisions of Articles 13e and 16. I lowever, the Commission has 
reworded Annex II, Part B, paragraph 5 in order to strengthen the risk assessment methodology. 
Amendment 65 specifies that the information submitted by the notifier concerning the monitoring 
plan shall include information on duration and frequency of the monitoring. This amendment 
clarifies the information requirement laid down in Annex III B, Part G, paragraph 4 and the 
Commission supports this amendment fully. 
Amendment 89 clarifies that the competent authorities may require the notifier to modify the 
conditions of, suspend or terminate the deliberate release of GMOs and to take any remedial 
action under Article 13e (5). The Commission accepts this amendment in principle. It clarifies 
the duties of  the competent authorities following receipt of  additional information concerning the 
potential risks posed by the release of a GMO and Article 13e has been amended accordingly, 
taking into account the changes which have been accepted in line with Amendments 31 and 43. 
4 The Commission cannot accept Amendments 2, 7, 8, 10, 13, 19,21-24,28, 30, 37, 40, 41, 45, 46, 
48-52,55,59,61, 63, 67, 68, 73, 75, 79, 84, 86, 87, 90, 91, 95,96 and 101. Commentary on these 
amendments is as follows. 
Amendments 2 and 22 seek to delete Article 5 and the corresponding recital, which allow the 
relevant Part B releases to be covered by specific product legislation containing an environmental 
risk assessment equivalent to that laid down in Directive 90/220/EEC. These amendments are not 
acceptable to the Commission, since this Article promotes· the link between releases for purposes 
of  research and development and product releases. 
Amendments 7 and 95 propose a new recital and a provision concerning environment liability 
rules. The Commission prefers to deal with this matter in a horizontal manner in order to avoid 
different liability requirements in different Directives and intends to produce a White Paper on 
environmental liability. These amendments arc, therel!>re, not acceptable. 
Amendments 8,  30,  48,  49,  50,  52,  63  and  87  are  not acceptable because  these  represent 
duplication of  other amendments or provisions in the text of  the Commission Proposal. They do 
not assist the clarity of  the text. 
Amendment 10 is not acceptable since it would significantly enlarge the scope ofthe Directive 
to cover "non-living" elements and chemical DNA. 
Amendment 13 seeks to introduce an exemption to the definition of  placing on the market. While 
acknowledging the intention to clarify further the definition of  the placing on the market in line 
with the current practice, the Commission feels that the explicit mentioning of one exemption 
might cause legal uncertainty about the scope of  the Directive. Amendment 40 is not consistent 
with Article 1 of  the Commission Proposal and would lead to a lack of  clarity. Accordingly, it 
is also not acceptable. 
Amendments 19, 21  and 51  propose the inclusion of  provisions concerning the import and export 
. of  GMOs. These amendments are not acceptable to the Commission, since they would prejudge 
the  final  text of a  Biosafety  Protocol,  which  is  being  negotiated  in  the  framework  of the 
Convention on Biolo'gical Div€;rsity. 
Amendment 23 has not been accepted by the Commission. It would increase the time periods that 
Competent Authorities have to review Category I applications and thus places additional burdens 
onnotifiers without increasing safety, since Category I releases meet specific criteria based on 
safety and familiarity. 
Amendment 24 seeks to introduce implicit consent for Category I experimental releases. The 
Commission considers that an explicit written consent is more appropriate in all cases of  releases 
and has, therefore, not accepted this amendment. 
Amendment 28 limits the notifier's choice of  appropriate application procedure and is, therefore, 
not acceptable. 
5 Amendments 37 and 67 address the labelling ofGMOs. The labelling policy of  the Commission 
implies that all GMOs covered by Directive 90/220/EEC must be labelled. In cases where the 
presence of GMOs, mixed with conventional produce, cannot be excluded but there is  no 
evidence of  any such presence of GMOs, the "may contain" label is allowed. This possibility, 
which intends to facilitate operations in early stages of  the production chain, is without prejudice 
to the requirements of  the Novel Foods Regulation which ensures that the final consumer is 
always and affirmatively informed about any presence of  GMOs or their modified products in 
foods  and  food  ingredients.  The -proposed  amendments,  therefore,  neither  improve  the 
information offered to final consumer, nor do they offer any added value to flexibility and the 
development of  information exchange throughout the production chain. 
Amendments 41, 45, and 46 seek to replace the 7 year time limitation by a 12 year time limitation 
for first-time consents. The principle of time-limited consent will allow aU  information to be 
reassessed and make it possible to .alter the consent conditions so that they reflect the state of 
scientific knowledge at that time. The Commission cannot accept these amendments because it 
considers that the period of 7 years is the optimum time needed to reassess a GMO and to re-
examine the initial consent conditions. The fixed period of 12 years would be too long for such 
a review. Amendment 75 requires the 12  year period for first-time  con~ents also in specific 
productlegislation and is not acceptable either.  · 
Amendment 55 proposes changes in the Illb comitology procedure. The involvement of the 
European Parliament in the comitology procedure is currently subject to the 'modus vivendi' and 
will  be foiinalised in a  specific  decision on the  new comitology.  This amendment is  not 
acceptable to the Commissio!l at this stage. 
Amendments 59, part I and 61  seek to introduce the evaluation of  socio-economic aspects as a 
basic principle into the environmental risk assessment. The basis of  the Directive is the protection 
of  the environment and human health. Therefore, the Commission cannot accept the inclusion of 
socio-economic aspects as a general principle into the scientific evaluation of  risks of  a GMO on 
a case by case basis. Amendment 59, part II does not clarify further the Commission Proposal and 
· is also not acceptable. 
Amendments 68 and I 0 I seek to change the criteria in Annex V which determine the GMOs 
which can be classified into Category I of Part B releases. It is proposed that certain types of 
GMOs be excluded from Category I on a general basis. These amendments are not acceptable, 
· since they do not follow the case by case principle and the structure of  Annex V. According to 
the Commission Proposal, certain GMOs may be classified on a case by ease basis into Category 
I, if  they meet specific criteria of  safety and familiarity. 
Amendments 73 and 90 have not been accepted by the Commission. These amendments propose 
a general ban for certain types of  GMOs in Directive 90/220/EEC. However, one basic principle 
of  the Directive is that a comprehensive scientific risk  assessment is carried out on a case by case 
basis  .. A general ban of  certain types of  GMOs is not consistent with this principle and does not 
improve the general balance in the Directive. The Commission is of  the opinion that the current 
practice  of a  case  by  case  based  risk  assessment  thoroughly  evaluates  the  effects  and 
consequences of  the insertion of  antibiotic resistance genes into a GMO. 
Amendment 79 seeks to exempt pharmaceutical products for human use containing or consisting 
' 
6 of  GMOs from the scope of  Directive 90/220/EEC provided that they ate covered by Community 
legislation, which provides for an equivalent risk assessment. The Commission cannot accept this 
. amendment, since it would go furtherthan Articles 5 and I 0 of  the Directive, which allow such 
products only to be removed trom the administrative procedures of the Directive and not from 
the general provisions. 
Amendment 84 addresses scientific uncertainties and the need for close co-operation between 
scientists and  policy-makers.  This recital  is  not  specifically linked to  the  legal  text of the 
Directive and is not acceptable to the Commission. 
Amendment 86 proposes that a notifier may take legal action, if  the competent authority does not 
respond  within the time period set out in the  proposed  Directive.  This amendment is  not 
acceptable, since this issue is covered by the national legal protection regimes, which apply in 
any case. 
Amendment 91  has hot been accepted by the Commission, since it is not consistent with the 
principle of  the case by case analysis. It seeks to introduce a general obligation for the Member 
States and the Commission to ensure that, when consenting to a deliberate release, measures are 
taken to prevent gene transfer from GMOs to other organisms. 
Amendment 96 seeks to introduce in a recital a political statement addressing the creation of  a 
centralised procedure at Community level for the release of  GMOs. This amendment is not linked 
to the legal text and is not acceptable to the Commission. 
7 Amended Proposal for a 
EUROPEAN PARLIAMENT AND COUNCIL DIRECTIVE 
amending Directive 90/220/EEC 
on the deliberate release into the envir{)nment of  genetically modified organisms 
(presented by the Commission pursuant to Article 189a paragraph 2 of  the EC Treaty) 
COMMISSION PROPOSAL  AMENDED PROPOSAL 
Recital I 
Whereas,  under  the  Treaty,  action  by  the 
Community  relating  to · the  environment 
should ·be  based  on  the  principle  that 
preventive action should be taken; 
Whereas,  under  the  Treaty,  action  by  the 
Community  relating  to  the  environment 
should  be  based  on  the  principle  that 
preventive action should be taken; whereas the 
precautionary principle has been taken into 
account in the drafting of  this Directive; 
Recital4a (new) 
Whereas means shall be sought of  providing 
possibilities to facilitate the control of  GMOs 
or their retrieval in the event of  an acute· risk; 
Recital 5 
Whereas  the  provisions  of  the  Directive 
concerning Part B releases of products shall 
not  apply  to  products  under  development 
covered  by  Community  legislation  which · 
provides  for  a  specific  environmental  risk 
assessment similar to  that laid down in  this 
Directive; 
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Whereas  the  provisions  of the  Directive 
concerning Part B releases of products shall 
not  apply  to  products  under  development 
covered  by  Community  legislation  which 
provides  for  a  specific  environmental  risk 
assessment  at  least  equivalent  to  that  laid 
down in this Directive; Recital Sa (new) 
Whereas the environmental risk assessment of 
this  Directive  concerning  Part  C  releases 
should be  a point of reference for  products 
containing, or consisting of, GMOs covered 
by other Community legislation which should 
therefore provide for a specific environmental 
risk assessment at least equivalent to that laid 
down in this Directive; 
Recital Sb (new) 
Whereas, for the renewal of consent, all the 
terms of  the original consent may be revised, 
including  those  such  as  monitoring  or the 
fixed period of  the consent; 
Recital 7 
Whereas  it  is  appropriate  that  the 
administrative procedure for granting consents 
_  to the placing on the market of  GMOs as or in 
products should become more efficient and 
more transparent and that consent should only 
be granted for a fixed period; 
Whereas  it  is  appropriate  that  the 
administrative procedure for granting consents 
to the placing on the market of  GMOs as or in 
products should become more efficient and 
more transparent and that first-time consent 
should be granted for a fixed period; 
Recital 12 
Whereas the  Commission may  consult any 
committee  it  has  created  with  a  view  to 
advising  it  on  the  ethical  implications  of 
biotechnology on general matters which in the 
view of the  Commission may  raise  ethical 
concerns; 
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Whereas the Commission's European Group 
on Ethics in Sc'ience and New Technologies 
may  be consulted with a view to obtaining 
advice  on ethical  issues  of general  nature 
~regarding the deliberate release of  GMOs; Article 2 ( 1) 
1. 'organism' is any biological entity capable 
of  replication  or  of  transferring  genetic 
material; 
1. 'organism' is any biological entity, with the 
exception of  humans, capable of  replication or 
of  transferring genetic material; 
Article 2~(3a) (new) 
3a. 'unauthorised dclibemte release' means any 
deliberate release of  GMOs as or in products 
for which no authorisation WaS given; 
Article 2 (3b) (new) 
3b. 'product' means a preparation consisting 
of, or containing, a GMO or a combination of 
GMOs, which is placed on the market; 
Article 2 (5) 
5.  'notification'  means  the  presentation  of 
documents  contammg  the  reqUisite 
information to the competent authority of a 
Member  State.  The  person  making  the 
presentation  shall  be  referred  to  as  'the 
notifier'; 
5.  'notification'  means  the  presentation  of 
documents  containing  the  requisite 
information to, and if  appropriate, the lodging 
of  samples  of  the  GMO  or  its  genetic 
materials with, the competent authorities of  a 
Member  State.  The  person  making  the 
presentation  shall  be  referred  to  as  'the 
notifier'; 
Article 2 (6) 
6. 'environmental risk assessment' means the 
evaluatio~;:t of the direct and indirect risks to 
human health and the environment which the 
deliberate  release  of  GMOs  into  the 
environment may pose; 
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6. 'environmental risk assessment' means the 
evaluation ofthe direct2 indirect, immediate or 
delayed  risks  to  human  health  and  the 
environment which the deliberate release of 
GMOs into the environment may. pose; Article 2 (6a) (new) 
6a.  'use'  means  the  deliberate  release  of a 
product which has been placed on the market. 
The  persons  carrying  out this  use  will  be 
referred to as 'users'. 
Article 4 (3) 
Member States shall ensure that the competent 
authorities  organizes  inspections  and  other 
control  measures  as  appropriate,  to  ensure 
compliance with this Directive. 
Member States shall ensure that the competent 
authorities  organizes  inspections  and  other 
· control  measures  as  appropriate,  to  ensure 
compliance with this Directive. In the event of 
an unauthorised deliberate release of GMOs 
the Member State concerned shall ensure that 
n~cessary measures are taken to terminate the 
release,  to  initiate  remedial  action  and  to 
inform other Member States, the Commission 
and the public. 
Article 5 
Articles 6 to 9 shall not apply to any products 
under development covered by  Community 
legislation  which  provides  for  a  specific 
environmental risk assessment similar to that 
laid down in those Articles. 
ll 
Articles 6 to 9 shall not apply to any products 
under development covered by Cominunity 
legislation  which  provides  tbr  a  specific 
environmental  risk  assessment  at  least 
equivalent to  that laid down in Annex II  of 
this Directive. ,, 
I 
I 
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Article 6b (2) 
The  notification referred to  in  paragraph  1 
shall include a technical dossier supplying the 
information specified in Annex III necessary 
for evaluating any foreseeable risks from the 
deliberate release of  a GMO or combination of 
GMOs, in particular: 
a)  general information including information 
"'  on personnel and training, 
b)  information relating to the GMO(s), 
c)  information relating to  the conditions of 
release and the receiving environment, 
d)  information on the interactions between 
the GMO(s) and the environment, 
e)  information on monitoring, control, waste 
treatment and emergency response plans, 
f)  a  statement evaluating  the  impacts  and 
risks  posed  by  the  GMO(s)  to  human 
health or the· environment from the uses 
envisaged. 
The  notification referred to. in  paragraph  1 
shall include a technical dossier supplying the 
information specified in Annex III necessary 
for evaluating any foreseeable risks from the 
deliberate release of a GMO or combination 
of  GMOs, in particular: 
a)  general information including information 
on personnel and training, 
b)  information relating to the GMO(s), 
c)  information relating to the conditions of 
release and the receiving environment, 
d)  information on the  interactions between 
. the GMO(s) and the environment, 
e)  a detailed plan for monitoring in order to 
identify  any  relevant  direct,  indirect, 
immediate or delayed effects of  the GMOs 
on human health or the environment, 
f)  information on control, remediation, waste 
treatment and emergency response plans, 
g)_  ·a  statement  evaluating  the  impacts  and 
risks  posed  by  the  GMO(s)  to  human 
health or the environment from the uses 
envisaged. 
Article 6d (2) 
2.  If  information  becomes  available 
subsequently to the competent authority which 
could have significant consequences for the 
risks  posed  by  the  release,  the  competent 
authority may require the notifier to  modify 
the conditions of,  suspend or  terminate the 
deliberate release. 
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2.  If  information  becomes  available 
subsequently to the competent authority which 
could have significant consequences for the 
risks  posed  by  the  release,  the  competent 
authority shall evaluate such information and 
may  require  the  notifier  to  modify  the 
conditions  of,  suspend  or  terminate  the 
deliberate release. -----·---··----~--~  .. ==·-·==-==-'*===·===================::-
Article 7 
Without prejudice to the provisions of  Article 
19, Member States shall make available to the 
public  information  on  Part  B  releases  of 
GMOs. To the extent  feasible and appropriate, 
Member States shall inform and consult the 
public  on  any  aspect  of  the  proposed 
deliberate release in an adequate, effective and 
timely manner. Any such public participation 
procedure  shall  not  exceed  90  days.  The 
· Commission  shall_  lay  down,  pursuant  to 
Article 21, the manner in which· this public 
participation procedure shall take place before 
..... [the date foreseen for the transposition of 
the amending Directive]. 
Article 8 
After completion of  a release and, thereafter, 
at the intervals laid down in the consent, the 
notifier shall inform the competent authority 
of the result of the release in respect of any 
risk to human health or the environment, with 
particular reference to anl' kind of  product that 
the  notifier mal'  intend  to  notify  at  a  later 
stage.  The  summaries of the results of the 
release,  including  any· data  resulting  from 
monitoring,  shall  be  made  available to  the 
Commission and the other Member States. 
Article 9 (2) 
2. The Commission shall immediately forward 
these summaries to the other Member States, 
which  may,  within  30  days,  present 
observations  through  the  Commission  or 
directly. 
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2. The Commission shall immediately forward 
these summaries to the other Member States, 
which  may,  within  30  days,  present 
observations  through  the  Commission  or 
directly. At their request, Member States shall 
be  permitted  to  receive  a  COPY  of the  full 
notification from the competent authorit)::' of 
the relevant Member State. Article 10 
1.  Articles  I I  to  I 8 shaH not apply  to  any 
products covered by Community legislation 
which provides for a spccitic environmental 
risk assessment similar to  that laid down in 
this Directive. 
Articles  II  to  18  shall  not  apply  to  any 
products covered by  Community legislation 
which provides for a specific environmental 
risk assessment at least equivalent to that laid 
down in Annex II of  this Directive. 
Article 12 (3) 
3.  The  assessment  report  shall  indicate 
whether the GMO(s) in  question should  be 
placed  on ·the  market  and  under  which 
conditions,  if any,  or  whether  additional 
assessment is required. 
The assessment reports shall be established in 
accordance with the guidelines laid down in 
Annex VI. 
The assessment report shall indicate 
i2 whether the GMO(s) in question should be 
placed  on  the  market  and  under  what 
conditions, if  any, 
ii) whether the dMO(s) in question shall not 
be placed on the market or 
@ whether additional assessment is required. 
The as·sessment reports shall be established in 
accordance with the guidelines laid down in 
Annex VI. 
Article 12 (3a) (new) 
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3a. In the case referred to in paragraph 3 (ii), 
the .  competent  authority  shall  inform  the 
notifier that the release  does  not fulfil  the 
conditions  of this  Directive  and  that  it  is 
. therefore  rejected  at  the  same  time  as  it 
forwards  its  assessment  report  to  the 
Commission. Article 13c (4) 
4. In the absence of any reasoned objection 
from  a  Member  State  or  the  Commission 
within  30  days  following  the  date  of 
·submission  referred  to  in  paragraph  3,  the 
competent authority that received the original 
notification shall give its consent in writing 
for  the renewal of the  original  consent and 
shall inform the other Member States and the 
Commission  thereof.  The  consent  shall  be 
granted for a fixed period of seven years. 
4.  In the absence of any reasoned objection 
from  a  Member  State  or  the  Commission 
within  30  days  following  the  date  of 
submission  referred  to  in  paragraph  3,  the 
competent authority that received the original 
notification shall give its consent in writing 
for  the renewal of the original -consent  and 
shall inform the other Member States and the 
Commission thereof The period of  validity of 
the consent may be limited as appropriate. 
Article 13d ( 1) 
1.  In cases where ari objection is  raised and 
maintained in accordance with Article 13(2), 
I3b(5) or 13c(3), or an additional assessment 
is required in accordance with Article 12(3), 
the Commission shall take a decision within 
three months in accordance with the procedure 
laid down in Article 21. 
For the purpose of  calculating the three month 
period, any period of time during which the 
Commission is awaiting further information 
which it may have requested from the notifier 
or is  seeking  the  opinion  of a  Scientific 
Committee which has been consulted shall not 
be taken into account. 
l. In cases where an objection is raised and 
maintained in accordance with Article 13(2), 
13b(5) or 13c(3), or an additional assessment 
is required in accordance with Article 12(3), 
the Commission· shall take a decision within 
three months in accordance with the procedure 
laid down in Article 21. 
For the purpose of  calculating ·the three month 
period, any period of time during which the 
Commission is awaiting further information 
which it may have requested from the notifier 
or  is  seeking  the  opinion  of a  Scientific 
Committee  which  has  been  consulted  in 
accordance with Article 20a (1) shall not be 
taken into account.· 
Artide 13e (3) 
3.  Consent to the placing on the market of 
GMOs in or as a product shall be granted for 
a fixed period of  seven years. The notifier may 
proceed with the placing on the market only 
when he has received the written consent of 
the competent authority in  accordance with 
Articles  13,  13b,  13c  and  13d,  and  in 
conformity  with  any  conditions,  including 
reference  to  particular  ecosystems/ 
environments, required in that consent. 
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3.  Without  prejudice  to  Article  13c  (4), 
~onsent to the placing on the market ofGMOs 
in or as a product shall be granted for a fixed 
period  of seven  years.  The  notitier  may 
proceed with the placing on the market only 
when he has received the written consent of . 
the competent authority in accordance with 
Articles  13,  13b,  13c  and  13d,  and  in 
conformity  with  any  conditions,  including 
reference  to  particular  ecosystems/ 
environments, required in that consent: 
r Article 13c (5) 
5.  If  the  competent  authority  receives 
additional information pursuant to paragraph 
4, it shall immediately inform the Commission 
and  the  competent  authorities  of the  otheJ 
Member States. 
5.  If  the  competent  authority  receives 
additional information pursuant to paragraph 
4, or otherwise, which could have significant 
consequences  for  the  risks  posed  by  the 
release, the competent authority.shall evaluate 
such. information,  and  it shall  immediately 
inform the Commission _and  the competent 
authorities of  the other Member States of  the 
action taken. 
Article 16(1) 
1. Where a Member State, as a result of new 
information  or  reassessment  of  existing 
information,  has  detailed  grounds  lor 
considering that a  product which  has  been 
properly  notified  and  has  received  written 
consent under this Directive constitutes a risk 
to  human  health  or  the  environment,  that 
Member State may provisionally restrict or 
~  prol}ibit the use and/or sale of  that product on 
its territory.  It shall immediately inform the 
Commission and the other Member States of 
such action and give reasons for its. decision. 
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1.  Where  a  Member  State,  as  a  result  of 
additional  information  or reassessment of 
existing information, has detailed grounds tor 
considering  that a  product which  has  been 
properly  notified  and  has  received  written 
consent under this Directive constitutes a risk 
to  human  health  or the  environment,  that 
Member State may provisionally restrict or 
prohibit the use and/or sale of  that product on 
its territory. 
In the event of an acute risk, the deliberate 
release shall be terminated immediately and, 
as  far  as  possible,  the  GMOs  shall  be 
recovered .  In  addition, the public shall  be 
informed of  the risk posed by the GMOs. 
The Member State shall immediately inform 
the Commission ~nd  the other Member States 
of  such  action  and  give  reasons  for  its 
decision. Article 20a 
The relevant Scientific Committee(s) shall be 
consulted by the Commission on any matter 
which is likely to  have an  effect on human 
health  and/or  the  environment  before  the 
decision  procedure  referred  to  in  Articles 
13d(l) or 16(2) is initiated. 
1. The relevant Scientific Committee(s) shall 
be  consulted  by  the  Commission  on  any 
matter which  is  likely  to  have  an  enect on 
human health and/or the environment before 
the decision procedure referred to in Articles 
I 3d( 1) or 16(2) is initiated. The Commission 
may require the adoption of  an opinion by the 
Scientific  Committee(s)  within  a  specified 
time period. 
2. The Commission, on its own initiative or at 
the  request of the Council or the  European 
Parliament, may consult its European Group 
on Ethics in Science and New Technologies 
with a view to advising it on ethical issues of 
general nature regarding the release of  GMOs. 
ANNEX II (A) (I) 
1.  Elements  which  may  be  considered  as 
potentially harmful effects : 
- pathogenicity to humans, animals or plants 
- compromising of  prophylactic or therapeutic 
treatments 
- effects on population dynamics within the 
receiving environment 
- effects on geochemistry 
-the uncontrolledspread of  the GMO(s) in the 
environment  and  invasion  of  unrelated 
ecosystems 
" effects  resulting  from  the  transfer  of the 
inserted genetic material to other organisms 
- phenotypic and genetic instability. 
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l.  Elements  which  may  be  considered  as 
potentially harmful effects : 
- path?genicity to humans, animals, plants  or 
microorganisms 
- compromising of  prophylactic or therapeutic 
treatments 
- effects on population dynamics within the 
receiving environment 
- effects on geochemistry 
-the uncontrolled spread of  the GMO(s} in the 
environment  and  invasion  of  unrelated 
ecosystems 
- effects  resulting  from  the  transfer of the 
inserted genetic material to other organisms 
- phenotypic and genetic instability ANNEX II (B) (5) 
5.  Application of management strategies for 
risks from the deliberate release ofGMO(s) 
If for any release the estimated risk  for  any 
identified hazard is  not an acceptable level, 
the GMO(s) or the conditions of the release 
·  should be modified to reduce the risk. 
5.  Application of management strategies for 
risks from the deliberate release of  GMO(s) 
If for  any release the estimated risk for any 
identified hazard is  not an acceptable level, 
the GMO(s) or the conditions of the release 
shall be modified in such a way as to reduce -
the risk to an acceptable level. 
ANNEX IIII3 (G) (4) 
4.  Description  of  monitoring  plans  and 
techniques. 
4.  Description  of monitoring  plans  and 
techniques and their duration and frequency. 
ANNEX IV (A) (5) 
5.  information  relating  to  the  introduced 
genetic modification which could be of 
relevance  to  the  establishment  of  a 
possible  register  of  modifications 
introduced in  organisms (species).  This 
may include nucleotide sequences or other 
type of information which is relevant to 
the inclusion in such a register. 
5.  information  relating  to  the  introduced 
genetic modification which~  of  relevance 
for the detection and identification of  the 
GMO(s)  to  facilitate  post~marketing 
control and inspection. This may include 
nucleotide  sequences  or  other  type  of 
information  which  is  relevant  to  the 
inclusion  in  a  register  regarding  the 
control of  GMOs released tor placing on 
the market. 
ANNEX IV (B) (6) (new) 
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6.  description of  procedures which facilitate 
the retrieval of  the GMOs in the event of 
an acute risk. Annex VI (5) 
5.  A conclusion on whether the GMO(s) in 
question should be placed on the market in 
or  as  (a)  product(s)  and  under  which 
conditions  or  whether  an  additional 
assessment is required on certain aspects. 
The  aspects  which  require  additional 
assessment should be specified. 
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5.  A conclusion on whether the GMO(s) in 
question should be placed on the market in 
or  as  (a)  product(s)  and  under  which 
conditions,  whether  the  GMO(s)  in 
question shall not be placed on the market 
or whether  an  additional  assessment  is 
required  on  certain aspects. The aspects 
which  require  additional  assessment 
should be specified. In the case that it has 
been  concluded  that  the  GMO(s)  in 
question shall not be placed on the market, 
the competent authority shall give reasons 
for its decision. ISSN 0254-1475 
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